Recombinant Hepatitis E Vaccine (Escherichia Coli)

China Recombinant Hepatitis E Vaccine (Escherichia Coli), Find details about China Hepatitis E, Vaccine from Recombinant Hepatitis E Vaccine (Escherichia Coli)

Model NO.
YY-1155
Pharmaceutical Technology
Chemical Synthesis
Drug Reg./Approval No.
S20110021
Trademark
Mevac E
Specification
1 ml/ 1 pre-filled syringe/ 1 box
Origin
China
HS Code
3002200
Model NO.
YY-1155
Pharmaceutical Technology
Chemical Synthesis
Drug Reg./Approval No.
S20110021
Trademark
Mevac E
Specification
1 ml/ 1 pre-filled syringe/ 1 box
Origin
China
HS Code
3002200

Indications   

It can stimulate the body to produce immunity against hepatitis E virus for the prevention of hepatitis E.

 

Highlights

1. The first Hepatitis E vaccine in the world , launched in 2012

2. 100% protection rate and good safety had been proven in large-scale phase III clinical trial(> 110000 subjects)

3. It's predicted that immune persistence can last >10 years

4. Complete phase I, II, III clinical trial conducted in China

5. Being registered in India, Thailand, Nepal, Pakistan.

 

Specification

Each 0.5 ml dose contains 30μg of purified recombinant hepatitis E virus antigen.
 

History:
Shenzhen Mellow Hope Pharm Industrial Co., Ltd. is specializing in exporting biological products such as human vaccines, plasma products, etc. After nearly two decades of unremitting efforts, Mellow Hope has developed into one of the largest exporters of human vaccines in China, and has established a wide distribution and sales network throughout South Asia, Southeast Asia, Central Asia, Middle East, Latin America and Africa. 
Our experts can provide to our global partners with professional knowledge and service in the activity of products registration, launching and distribution:
Ø Insight on potential needs in the local market, a full basket of high-quality products provided to our partners for their choices.
Ø General biological products' information and knowledge. 
Ø Preparation of registration dossiers to meet diverse regulatory requirements.
Ø Coordination of international inspections.
Ø Cold-chain transportation and punctual delivery of products.
Ø Abundant promotion materials and marketing activities of products.
Adhering to the "Integrity, Cooperation and Win-win" business principles, we will, as always, continue to promote biological products in global market, build a long-term partnership with our partners in the world and strive to become the strongest supplier of biological products from China to the world.

 

Recombinant Hepatitis E Vaccine (Escherichia Coli)